415 results on '"Garassino, M.C."'
Search Results
2. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
3. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review
4. Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey
5. PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers
6. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
7. Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies
8. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
9. Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey
10. Social distress among medical oncologists and other healthcare professionals during the first wave of COVID-19 pandemic in Italy
11. Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy
12. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
13. OA22.03 The Addition of Multisite SBRT to Ipilimumab and Nivolumab in First Line Metastatic NSCLC: The COSINR Trial
14. OA21.06 ctDNA Dynamics, Prognostic Markers and Resistance Mechanisms in Tepotinib-Treated METex14 Skipping NSCLC in the VISION Trial
15. 1541MO Leadership roles in oncology: Gender is still a barrier. Results from the new ESMO Women for Oncology Committee authorship and monitoring studies
16. 1314P Patient-reported outcomes (PROs) from the phase III EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel (doc) in metastatic non-small cell lung cancer (mNSCLC)
17. PPD02.03 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Analysis of All Patients From VISION Cohorts A and C
18. OA01.05 Three-year Outcomes per PD-L1 Status and Continued Cemiplimab Beyond Progression + Chemotherapy: EMPOWER-Lung 1
19. PP01.01 PEOPLE (NTC03447678), a Phase II Trial to Test Biomarkers of Response to Pembrolizumab as First-Line Treatment in Advanced NSCLC Patients with PD-L1>50%
20. LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
21. 25P Platinum-based chemotherapy (PCT) addition to first-line PD-1/PD-L1 inhibitors (ICI) prevent hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) patients (pts) by reducing circulating immature neutrophils
22. 122MO Cemiplimab (cemi) + platinum doublet chemotherapy (chemo) + ipilimumab (ipi) for first-line treatment of advanced non-small cell lung cancer (NSCLC): EMPOWER-Lung 3 part I
23. 58O Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): Interim analysis from the PACIFIC-R study
24. 1394TiP KRYSTAL-7: A phase III study of first-line adagrasib plus pembrolizumab versus pembrolizumab alone in patients with advanced NSCLC with KRASG12C mutation.
25. 1210P Neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy and adjuvant pembro or pbo for early stage NSCLC: Subgroup analyses of the phase III KEYNOTE-671 study.
26. 1071P Trustworthy artificial intelligence models using real-world and circulating genomics data for the prediction of immunotherapy efficacy in non-small cell lung cancer patients
27. 1530P Durvalumab (D) + platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN
28. P1.15-02 Plasma microRNAs Modulation in Advanced NSCLC Patients Receiving Single Agent Immune Checkpoint Inhibitors
29. OA15.06 Pooled Analysis of Outcomes with Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer
30. 1189TiP Phase II study of anti-TIGIT GSK4428859A (GSK’859A)/EOS-448 + anti-CD96 GSK6097608 (GSK’608) + anti-PD-1 dostarlimab in non-small cell lung cancer (NSCLC)
31. 1056P KRAS and LKB1 mutation conferring prognostic and predictive role on liquid biopsy in advanced NSCLC
32. 1079P Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with novel actionable oncogenic driver alterations
33. EP08.01-006 Using Real World data to build effective predictive machine learining models for NSCLC patients treated with immune-based therapy
34. 973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC
35. EP08.02-108 Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA Study
36. 1057P Baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced by platinum-based chemotherapy (PCT) and ICI combinations
37. 1533P Atezolizumab (ATZ) plus carboplatin (Cb) and etoposide (eto) in patients with untreated extensive-stage small cell lung cancer (ES-SCLC): Results from the interim analysis of MAURIS trial
38. 985P Tepotinib outcomes according to prior therapies in patients with MET exon 14 (METex14) skipping NSCLC
39. P1.16-04 Phase 3 EVOKE-01 Study of Sacituzumab Govitecan vs Docetaxel in NSCLC After Prior Platinum and Checkpoint Inhibitors
40. EP07.01-021 Clinical and Biochemical Profiling of Pleural Mesothelioma Patients Treated With Immunotherapy
41. Targeting the MET gene for the treatment of non-small-cell lung cancer
42. 1320P Digital pathology predicts PD-L1 expression in metastatic NSCLC patients treated with immunotherapy
43. 1247P Radiotherapy (RT) patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients (pts) with Stage III unresectable non-small cell lung cancer (UR-NSCLC) treated with durvalumab (D) after chemoradiotherapy (CRT)
44. 1232P Assessing uncertainty and vulnerability of clinical trials with immune-checkpoint inhibitors and chemotherapy (ICI+CT) in early stage non-small cell lung cancer (NSCLC) by informative censoring and survival inferred fragility index (SIFI)
45. 141O Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study
46. 118P Impact of grade ≥2 pneumonitis (G2+ PNS) on patient reported outcomes (PROs) with durvalumab (D) after chemoradiotherapy (CRT) in unresectable stage III NSCLC
47. 108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
48. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
49. VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo)
50. Is impaired response to PD-1 blockers of high serum PD-1 patients related to immune complexes?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.